Hormone-resistant Prostate Cancer
55
0
4
29
Key Insights
Highlights
Success Rate
64% trial completion
Published Results
32 trials with published results (58%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
29.1%
16 terminated out of 55 trials
64.4%
-22.1% vs benchmark
4%
2 trials in Phase 3/4
110%
32 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (55)
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer
Feasibility of a New Technology for Isolating Circulating Tumour Cells
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer